Editorial companion

What stands out

Bloomberg highlighted a late-stage win: a personalized mRNA vaccine from Moderna and Merck cut melanoma recurrence when paired with Merck’s Keytruda, a result that shifts mRNA from pandemic tool to potential oncology weapon. That single trial outcome can change investor math for Moderna, lift Merck’s immuno-oncology narrative, and force fresh conversations about pricing for clinical-stage biotech. The program’s success landed alongside more mundane but relevant corporate news, like Estée Lauder topping estimates and Target nudging guidance, which together make this episode a cross-asset snapshot of where risk appetite sits.